Clinical Trials

Advanced Solid Tumors

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Small Cell Lung Carcinoma

Solid Tumors

Advanced Solid Tumor

Solid Tumor

Mesothelioma, Thymoma, Neuroendocrine Tumors

Anus Neoplasms, Appendiceal Neoplasms, Ascites, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Laryngeal Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Penile Neoplasms, Stomach Neoplasms, Thymoma, Vulvar Neoplasms, Pleural Effusion, Malignant, Carcinoma, Neuroendocrine, Cholangiocarcinoma, Carcinoma, Small Cell, Carcinoma, Pancreatic Ductal, Gastrointestinal Stromal Tumors

Solid Tumor

Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

Solid Tumors

Advanced or Metastatic Solid Tumors

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Pleural Diseases

Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation

Solid Tumor Cancer

Patients With Advanced or Metastatic Solid Tumors